Taspoglutide与2型糖尿病常用药物的药物相互作用:五项I期试验结果
五项I期临床试验在健康受试者中评估了多重皮下注射taspoglutide(一种GLP-1激动剂)与赖诺普利、华法林、辛伐他汀、地高辛及含炔雌醇/左炔诺孕酮口服避孕药的潜在相互作用。结果显示,除辛伐他汀在taspoglutide给药日暴露显著降低外,其余药物暴露变化的90%CI均在0.7-1.3内,无临床相关凝血或排卵抑制改变,无需剂量调整。
要点
- Taspoglutide多次给药未对地高辛、口服避孕药、赖诺普利、华法林和辛伐他汀的药代动力学产生临床相关改变。
- 辛伐他汀在taspoglutide给药日暴露降低最明显,AUC降26%、Cmax降58%,活性代谢物暴露增加。
- 华法林凝血指标和口服避孕药排卵抑制活性未见临床相关变化,合用无需调整剂量。
核心结论
- Taspoglutide多次给药未导致地高辛、含炔雌醇和左炔诺孕酮的口服避孕药、赖诺普利、华法林和辛伐他汀的药代动力学发生具有临床相关性的改变,因此合用无需调整剂量。
研究设计与样本
- 五项临床药理学研究在健康受试者中评估多重皮下taspoglutide剂量与单剂量赖诺普利、华法林、辛伐他汀以及多剂量地高辛和口服避孕药的潜在药物相互作用。
- 采用几何均值比和90%置信区间量化最大血浆浓度和血浆浓度-时间曲线下面积的相互作用程度,并对华法林和口服避孕药进行药效学评估。
主要发现
- 在taspoglutide给药日,辛伐他汀的平均暴露降低:AUC降低26%、Cmax降低58%,其活性代谢物辛伐他汀β-羟基酸的平均暴露增加:AUC增加74%、Cmax增加23%。
- 其他受试药物虽观察到暴露的统计学显著变化,但Cmax和AUC的几何均值比的90%置信区间均在0.7-1.3区间内。
- 华法林的凝血指标和口服避孕药的排卵抑制活性未见临床相关变化。
关键数值与推荐
- 辛伐他汀在taspoglutide给药日AUC降低26%、Cmax降低58%,活性代谢物AUC增加74%、Cmax增加23%。
- 其他受试药物Cmax和AUC的几何均值比90%置信区间均在0.7-1.3内。
临床怎么用
- 临床合用taspoglutide与地高辛、口服避孕药、赖诺普利、华法林或辛伐他汀时无需调整剂量。
- 关注辛伐他汀在taspoglutide给药日的暴露降低及其活性代谢物暴露增加,但原文结论认为无临床相关性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Taspoglutide, a glucagon-like peptide-1 agonist, like native glucagon-like peptide-1, delays gastric emptying time and prolongs intestinal transit time, which may alter the pharmacokinetics of concomitantly administered oral drugs. The effect of taspoglutide on the pharmacokinetics of five oral drugs commonly used in patients with type 2 diabetes mellitus was assessed in healthy subjects. METHODS: Five clinical pharmacology studies evaluated the potential drug-drug interaction between multiple subcutaneous taspoglutide doses and a single dose of lisinopril, warfarin, and simvastatin and multiple doses of digoxin and an oral contraceptive containing ethinylestradiol and levonorgestrel. The extent of interaction was quantified using geometric mean ratios and 90% confidence intervals for the maximum plasma concentration and area under the plasma concentration-time curve. In addition to pharmacokinetics, pharmacodynamic effects were assessed for warfarin and the oral contraceptive. RESULTS: Among the tested drugs, the effect of taspoglutide on the pharmacokinetics of simvastatin was most pronounced, on the day of taspoglutide administration, the average exposure to simvastatin was decreased by - 26% and - 58% for the area under the plasma concentration-time curve and maximum plasma concentration, respectively, accompanied by an increase in average exposure to its active metabolite, simvastatin β-hydroxy acid (+ 74% and + 23% for area under the plasma concentration-time curve and maximum plasma concentration, respectively). Although statistically significant changes in exposure were observed for other test drugs, the 90% confidence intervals for the geometric mean ratio for maximum plasma concentration and area under the plasma concentration-time curve were within the 0.7-1.3 interval. No clinically relevant changes on coagulation (for warfarin) and ovulation-suppressing activity (for the oral contraceptive) were apparent. CONCLUSION: Overall, multiple doses of taspoglutide did not result in changes in the pharmacokinetics of digoxin, an oral contraceptive containing ethinylestradiol and levonorgestrel, lisinopril, warfarin, and simvastatin that would be considered of clinical relevance. Therefore, no dose adjustments are warranted upon co-administration.
引用
- Bogman K, Brumm J, Hofmann C, et al. Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials. Clin Pharmacokinet. 2019. PMID: 30968335. doi:10.1007/s40262-019-00757-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。